- 著者
- Hidenobu Okuyama Osamu Hirono Harutoshi Tamura Satoshi Nishiyama Yasuchika Takeishi Takamasa Kayama Isao Kubota
- 出版者
- 日本循環器学会
- 雑誌
- Circulation Journal (ISSN:13469843)
- 巻号頁・発行日
- vol.72, no.11, pp.1914-1914, 2008 (Released:2008-10-24)
The Editorial Team of Circulation Journal has recently confirmed that the paper written by Hidenobu Okuyama et al, published in the August 2008 issue of the Journal (Circ J 2008; 72: 1296 - 1302), contains serious plagiarism from the paper by Kenichi Sugioka et al, published in the April 2002 issue of Stroke (Stroke 2002; 33: 2077 - 2081). Therefore, we have had to take the decision to retract the offending paper from Circulation Journal. Hidenobu Okuyama, Osamu Hirono, Harutoshi Tamura, Satoshi Nishiyama, Yasuchika Takeishi, Takamasa Kayama, Isao Kubota. Impact of Aortic Arch Stiffness on Recurrence of Stroke in Patients With Acute Ischemic Stroke (Circ J 2008; 72: 1296 - 1302) As the Editor-in-Chief, I deeply regret that such misconduct has happened in our Journal, and would like to express the sincere hope and determination that it will never happen again in the future.
- 著者
- Miyuki Yokoyama Tetsu Watanabe Yoichiro Otaki Ken Watanabe Taku Toshima Takayuki Sugai Tetsuya Takahashi Daisuke Kinoshita Harutoshi Tamura Satoshi Nishiyama Hiroki Takahashi Takanori Arimoto Tetsuro Shishido Sou Yamauchi Tamon Yamanaka Takuya Miyamoto Isao Kubota
- 出版者
- The Japanese Circulation Society
- 雑誌
- Circulation Journal (ISSN:13469843)
- 巻号頁・発行日
- pp.CJ-17-0731, (Released:2017-11-30)
- 参考文献数
- 34
- 被引用文献数
- 40
Background:Peripheral artery disease (PAD) is an athero-occlusive disease and a known risk factor for cardiovascular events. The controlling nutritional status (CONUT) score and geriatric nutritional risk index (GNRI) are objective tools for evaluating malnutrition and are reportedly associated with poor clinical outcomes in patients with fatal diseases. However, the effect of malnutrition on the clinical outcomes in patients with PAD remains unclear.
- 著者
- Hiroshi Inoue Ken Okumura Hirotsugu Atarashi Takeshi Yamashita Hideki Origasa Naoko Kumagai Masayuki Sakurai Yuichiro Kawamura Isao Kubota Kazuo Matsumoto Yoshiaki Kaneko Satoshi Ogawa Yoshifusa Aizawa Masaomi Chinushi Itsuo Kodama Eiichi Watanabe Yukihiro Koretsune Yuji Okuyama Akihiko Shimizu Osamu Igawa Shigenobu Bando Masahiko Fukatani Tetsunori Saikawa Akiko Chishaki on behalf of the J-RHYTHM Registry Investigators
- 出版者
- 日本循環器学会
- 雑誌
- Circulation Journal (ISSN:13469843)
- 巻号頁・発行日
- pp.CJ-13-0290, (Released:2013-05-25)
- 参考文献数
- 24
- 被引用文献数
- 52 110
Background: Target anticoagulation levels for warfarin in Japanese patients with non-valvular atrial fibrillation (NVAF) are unclear. Methods and Results: Of 7,527 patients with NVAF, 1,002 did not receive warfarin (non-warfarin group), and the remaining patients receiving warfarin were divided into 5 groups based on their baseline international normalized ratio (INR) of prothrombin time (≤1.59, 1.6–1.99, 2.0–2.59, 2.6–2.99, and ≥3.0). Patients were followed-up prospectively for 2 years. Primary endpoints were thromboembolic events (cerebral infarction, transient ischemic attack, and systemic embolism), and major hemorrhage requiring hospital admission. During the follow-up period, thromboembolic events occurred in 3.0% of non-warfarin group, but at lower frequencies in the warfarin groups (2.0, 1.3, 1.5, 0.6, and 1.8%/2 years for INR values of ≤1.59, 1.6–1.99, 2.0–2.59, 2.6–2.99, and ≥3.0, respectively; P=0.0059). Major hemorrhage occurred more frequently in warfarin groups (1.5, 1.8, 2.4, 3.3, and 4.1% for INR values ≤1.59, 1.6–1.99, 2.0–2.59, 2.6–2.99, and ≥3.0, respectively; P=0.0041) than in non-warfarin group (0.8%/2 years). These trends were maintained when the analyses were confined to patients aged ≥70 years. Conclusions: An INR of 1.6–2.6 is safe and effective at preventing thromboembolic events in patients with NVAF, particularly patients aged ≥70 years. An INR of 2.6–2.99 is also effective, but associated with a slightly increased risk in major hemorrhage. (UMIN Clinical Trials Registry UMIN000001569)